WntResearch’s CEO to BioStock: “Aiming for an agreement”

WntResearch is approaching the first readout from the expansion part of the phase II study with Foxy-5 in colon cancer. In parallel, the company is working on business development where several potential partners are interested in taking part in the upcoming results, which are absolutely crucial for the project and the company:

– We are getting closer to a decision for WntResearch and Foxy-5. It will definitely be an exciting autumn, CEO Per Norlén writes in the Q2 report.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/08/wntresearchs-ceo-aiming-for-an-agreement/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se